New proposal for the staging of nonalcoholic steatohepatitis: Evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI

European Journal of Radiology

Volumn 73, Issue 1, 2010, Pages 137-142

  Tsuda, Natsuko ^a   Okada, Masahiro ^b   Murakami, Takamichi ^b  

^a BAYER YAKUHIN LTD   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Contrast media; Gd EOB DTPA; MRI; NASH; Rats

Indexed keywords

CONTRAST-ENHANCED; CONTROL GROUPS; DIETHYLENETRIAMINE PENTA-ACETIC ACIDS; FEEDING PERIOD; FLIP ANGLE; GD-DTPA; GD-EOB-DTPA; LIVER FIBROSIS; NON-ALCOHOLIC STEATOHEPATITIS; SIGNAL INTENSITIES; SPRAGUE-DAWLEY RATS; TIME COURSE;

CONTRAST MEDIA; FEEDING; LIVER; NUTRITION; RATS; TISSUE;

GADOLINIUM;

CONTRAST MEDIUM; GADOLINIUM ETHOXYBENZYL DIETHYLENNETRIAMINE PENTAACETIC ACID; GADOXETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; INFLAMMATION; LIVER FIBROSIS; MALE; MEDICAL LITERATURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT;

ALCOHOLISM; ANIMALS; CONTRAST MEDIA; FATTY LIVER; GADOLINIUM DTPA; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MALE; PILOT PROJECTS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 73649120977     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.09.036     Document Type: Article

References (30)

1. Tokushige K., Takakura M., Tsuchiya-Matsushita N., et al. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol (2007) [E-pub ahead of print]
2. Yamazaki Y., Kakizaki S., Horiguchi N., et al. The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut 56 4 (2007) 565-574
3. Iacobellis A., Maecellini M., Andriulli A., Perri F., Leandro G., and Devito R. Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. World J Gastroenterol 12 48 (2006) 7821-7825
4. Otogawa K., Kinoshita K., Fujii H., et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis. Am J Pathol 170 3 (2007) 967-980
5. Miele L., Forgione A., Gasbarrini G., and Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res 149 3 (2007) 114-125
6. Nakayama H., Otabe S., Ueno T., et al. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism 56 (2007) 470-475
7. Ito M., Suzuki J., Sasaki M., et al. Development of nonalcoholic steatohepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice. Hepatol Res 34 2 (2006) 92-98
8. Ikejima K., Okumura K., Lang T., et al. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res 33 2 (2005) 151-154
9. Tsuda N., Okada M., and Murakami T. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 42 4 (2007) 242-247
10. Halavaara J., Breuer J., Ayuso C., et al. Liver Tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-amulticenter trial. J Comput Assist Tomogr 30 3 (2006) 345-354
11. Jung G., Breuer J., Poll L.W., et al. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 47 1 (2006) 15-23
12. Bluemke D.A., Sahani D., Amendola M., et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 237 1 (2005) 89-98
13. Saito K., Kotake F., Ito N., et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 4 1 (2005) 1-9
14. Schuhmann-Giampieri G., Schmitt-Willich H., Press W.R., et al. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183 (1992) 59-64
15. Klumpp B., Fenchel M., Hoevelborn T., et al. Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 tesla. Invest Radiol 41 9 (2006) 661-667
16. Uhl M., Saueressig U., Buiren M., et al. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 41 8 (2005) 618-623
17. Knopp M.V., Balzer T., Esser M., Kashanian F.K., Paul P., and Niendorf H.P. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 41 6 (2006) 491-499
18. Kawaguchi K., Sakaida I., Tsuchiya M., Omori K., Takami T., and Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined diet. Biochem Biophys Res Commun 315 (2004) 187-195
19. Sakaida I., Tsuchiya M., Kawaguchi K., Kimura T., Terai S., and Okita K. Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline deficient l-amino acid-defined diet. J Hepatol 38 (2003) 762-769
20. Bergheim I., Guo L., Davis M.A., Duveau I., and Arteel G.E. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 316 2 (2006) 592-600
21. Li C.H., Piao D.M., Xu W.X., Yin Z.R., Jin J.S., and Shen A.S. Morphological and serum hyaluronic acid, laminin and type IV collagen changes in dimethylnitrosamine-induced hepatic fibrosis of rats. World J Gastroenterol 11 48 (2005) 7620-7624
22. Li J., Niu J.Z., Wang J.F., Li Y., and Tao X.H. Pathological mechanisms of alcohol-induced hepatic portal hypertension in early stage fibrosis rat model. World J Gastroenterol 11 41 (2005) 6483-6488
23. Lydatakis H., Hager I.P., Kostadelou E., Mpousmpoulas S., Pappas S., and Diamantis I. Clinical studies: non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int 26 7 (2006) 864-871
24. Libra A., Fernetti C., Lorusso V., et al. Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. J Pharmacol Exp Ther 319 2 (2006) 809-817
25. van Montfoort J.E., Stieger B., Meijer D.K., Weinmann H.J., Meier P.J., and Fattinger K.E. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 290 (1999) 153-157
26. Pascolo L., Cupelli F., Anelli P.L., et al. Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun 257 (1999) 746-752
27. Guardigli M., Marangi M., Casanova S., Grigioni W.F., Roda E., and Roda A. Chemiluminescence quantitative immunohistochemical determination of MRP2 in liver biopsies. J Histochem Cytochem 53 12 (2005) 1451-1457
28. Geier A., Dietrich C.G., Voigt S., et al. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 38 2 (2003) 345-354
29. Kojima H., Nies A.T., König J., et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol 39 (2003) 693-702
30. Geier A., Kim S.K., Gerloff T., et al. Hepatobiliary organic anion transporters are differentially regulated in acute toxic liver injury induced by carbon tetrachloride. J Hepatol 37 (2002) 198-205